Through the mentorship and guidance of the ICURe programme, KlasTx was awarded a circa £300,000 grant from Innovate UK. This grant allowed KlasTx to focus on preclinical developments which will aid in commercialisation pathway of our proprietary technology.
This project follows on from the successful Innovate UK market discovery programme ‘Innovation to commercialisation of University research’ (ICURe), with a comprehensive package of work to increase both the technology and investor readiness level of this innovative discovery, increasing the likelihood of ultimate patient benefit.